Jefferies analyst Matthew Taylor maintained a Hold rating on Teleflex (TFX – Research Report) today and set a price target of $145.00.
Matthew Taylor has given his Hold rating due to a combination of factors impacting Teleflex’s financial outlook. The company reported first-quarter revenues that slightly exceeded expectations, but there were notable declines in certain segments such as Anesthesia and OEM, which were offset by gains in other areas like Vascular Access and Surgical. Additionally, geographical performance varied, with the Americas showing better results compared to weaker performances in EMEA and Asia, partly due to challenges in China.
Teleflex’s guidance for the fiscal year reflects a cautious stance, maintaining organic sales growth projections but lowering EPS expectations due to tariff-related headwinds. The company is facing significant tariff impacts, particularly from China and Mexico, which are expected to affect costs in the latter half of the year. While management is exploring mitigation strategies, including supply chain adjustments and pricing actions, these efforts may take time to materialize. Consequently, Taylor’s Hold rating reflects the uncertainty and potential risks associated with these factors, despite some positive developments in certain business areas.
According to TipRanks, Taylor is a 5-star analyst with an average return of 7.3% and a 55.05% success rate. Taylor covers the Healthcare sector, focusing on stocks such as Boston Scientific, Dexcom, and Edwards Lifesciences.
In another report released on April 16, Mizuho Securities also maintained a Hold rating on the stock with a $155.00 price target.